Metabolic Health (Human)(27 expert discussions analyzed)

The most important finding across all 27 episodes is that insulin resistance — the state in which cells stop responding normally to insulin, forcing the pancreas to produce more — appears to be a common upstream driver connecting type 2 diabetes, cardiovascular disease, fatty liver disease, visceral fat accumulation, and possibly neurodegeneration and some psychiatric conditions. This is no longer a niche hypothesis: it is increasingly mainstream in metabolic medicine, supported by cohort research, mechanistic studies, and multiple randomized controlled trials showing that reducing refined carbohydrate intake lowers fasting insulin and improves metabolic markers. How much of cardiovascular risk insulin resistance explains relative to LDL and other pathways remains actively debated, and that disagreement is set out below. The practical implication is that treating these conditions as separate problems with separate solutions may miss a shared root cause that responds to shared interventions.

The gut microbiome emerges as a second major lever. Research from ZOE (published in Nature, led by Nicola Segata and Sarah Berry) and clinical gastroenterologist Will Bulsiewicz converge on the finding that dietary fiber diversity is the strongest single input for microbiome health. The mechanism is specific: gut bacteria ferment fiber into short-chain fatty acids — compounds called butyrate, acetate, and propionate — that activate appetite-regulating hormones including GLP-1 and PYY, the same hormones targeted by drugs like Ozempic. A low-fiber gut also allows bacterial products called lipopolysaccharides to leak into the bloodstream, potentially driving chronic inflammation and worsening insulin resistance. The practical takeaway — eat 30 or more distinct plant foods per week — does not require a microbiome test or a subscription and is supported by intervention data showing measurable microbiome shifts within weeks.

Alcohol's metabolic costs are more substantial than most people assume, even at moderate intake. Andrew Huberman's synthesis of the UK Biobank data (over 35,000 subjects) shows that one to two drinks per day is associated with measurable neocortical thinning and white-matter differences. Alcohol disrupts sleep architecture — shortening deep sleep and fragmenting the second half of the night — which compounds metabolic harm because sleep deprivation independently drives insulin resistance. Alcohol also elevates baseline cortisol, disrupts the gut microbiome, and is associated with a 4 to 13 percent increase in breast cancer risk per 10 grams per day through multiple mechanisms. The population-level consensus has shifted: 'less is better' is now the dominant public health framing, replacing the older 'moderate drinking is protective' narrative.

Ketogenic and low-carbohydrate eating represent a spectrum of interventions with meaningfully different evidence bases. At the aggressive end, a true ketogenic diet — defined by measurable blood ketone levels of 0.5 to 3.0 millimoles per liter — has decades of randomized controlled trial support for drug-resistant epilepsy and growing evidence for type 2 diabetes management. Dominic D'Agostino and Andrew Koutnik both emphasize that most people running 'keto' are not actually achieving therapeutic ketosis because they are not measuring ketones or managing electrolytes. For most adults with insulin resistance, a moderate low-carbohydrate approach (100 to 150 grams of total carbohydrates per day) captures most of the metabolic benefit with far greater adherence. David Unwin's primary-care cohort data shows type 2 diabetes remission rates of roughly 50 percent or higher in selected patients using sustainable low-carb protocols, consistent with the DiRECT trial results.

The most speculative but potentially important frontier is metabolic psychiatry. Harvard psychiatrist Chris Palmer argues that mitochondrial dysfunction and impaired brain energy metabolism may contribute to treatment-resistant depression, bipolar disorder, and other psychiatric conditions — and that supervised ketogenic intervention may complement standard psychiatric care for some patients. The evidence base here is strongest for epilepsy (where the ketogenic diet is established standard care), emerging for bipolar disorder through case series and small trials, and preliminary for other conditions. This is not a replacement for standard psychiatric treatment; it is a complementary framework that may matter most for people whose current treatment is incomplete.